IDYA

IDYA

USD

IDEAYA Biosciences Inc. Common Stock

$30.240+0.800 (2.717%)

即時價格

Healthcare
生物科技
美國

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$29.440

最高

$30.450

最低

$28.840

交易量

0.19M

公司基本面

市值

2.7B

行業

生物科技

國家

United States

交易統計

平均交易量

1.21M

交易所

NMS

貨幣

USD

52週範圍

最低 $13.45當前 $30.240最高 $33.64

相關新聞

PR Newswire

IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, provided a business update and announced financial results...

查看更多
IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
PR Newswire

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

查看更多
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR Newswire

IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

查看更多
IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events
Analyst Upgrades

JP Morgan Maintains Overweight on IDEAYA Biosciences, Raises Price Target to $79

JP Morgan analyst Anupam Rama maintains IDEAYA Biosciences with a Overweight and raises the price target from $74 to $79.

查看更多
JP Morgan Maintains Overweight on IDEAYA Biosciences, Raises Price Target to $79
Analyst Upgrades

Goldman Sachs Maintains Neutral on IDEAYA Biosciences, Raises Price Target to $30

Goldman Sachs analyst Corinne Jenkins maintains IDEAYA Biosciences with a Neutral and raises the price target from $27 to $30.

查看更多
Goldman Sachs Maintains Neutral on IDEAYA Biosciences, Raises Price Target to $30
Analyst Upgrades

RBC Capital Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $41

RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences with a Outperform and raises the price target from $38 to $41.

Analyst Upgrades

BTIG Reiterates Buy on IDEAYA Biosciences, Maintains $62 Price Target

BTIG analyst Justin Zelin reiterates IDEAYA Biosciences with a Buy and maintains $62 price target.